News

Fumiyo wrote  a short review article with Fuminori Tokunaga (Osaka City Univ) describing how defect of linear ubiquitination induced by LUBAC may correlate with human diseases such as autoimmunes and neurodegenerative diseases. We also disucssed potential applications of LUBAC inhibitors.

Tokunaga F, Ikeda F. Linear ubiquitination in immune and neurodegenerative
diseases, and beyond. Biochem Soc Trans. 2022 Mar 28:BST20211078. doi:
10.1042/BST20211078. Epub ahead of print. PMID: 35343567.

Our work on “The ubiquitin ligase HOIL-1L regulates immune responses by interacting with linear ubiquitin chains” is now online (iScience). Carlos, the last PhD student of the Ikeda Lab at IMBA (Austria) did a great job here.

“The ubiquitin ligase HOIL-1L regulates immune responses by interacting with linear ubiquitin chains”
Carlos Gomez-Diaz, Gustav Jonsson, Katrin Schodl, Luiza Deszcz, Annika Bestehorn, Kevin Eislmayr, Jorge Almagro, Anoop Kavirayani, Mayu Seida, Lilian M Fennell, Astrid Hagelkruys, Pavel Kovarik, Josef M Penninger, Fumiyo Ikeda

The Ikeda lab (MIB, Japan and IMBA, Austria) and the Haselbach lab (IMP,  Austria) published a paper entitled “The linear ubiquitin chain assembly complex LUBAC generates heterotypic ubiquitin chains” in eLife.

In this study, we found that LUBAC generates heterotypic ubiquitin chains (oxyester bond-based branching on the linear ubiquitin chains) dependently on the catalytic site in the HOIL-1L RING2 domain. We also revealed the first 3D structural model of an E3 ligase complex called LUBAC.

This was a work of Alan of his PhD study. Congratulations to everyone who was involved!

(created by https://www.wordclouds.com/)